Additional file 1 of Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis
Creators: name: Kadakia, Aditi
name: Dembek, Carole
name: Heller, Vincent
name: Rajpal Singh
name: Uyei, Jennifer
name: Hagi, Katsuhiko
name: Nosaka, Tadashi
name: Loebel, Antony
Publisher: name: figshare
Year: 2021
Subjects: subject: Genetics
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Neuroscience
subject: Pharmacology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: FOS: Chemical sciences
subject: 111714 Mental Health
subject: FOS: Health sciences
subject: FOS: Health sciences

description: Additional file 1: Table 1. The PRISMA 2020 Statement. Table 2a. Search Strings. Table 2b. Conference Proceedings Reviewed. Table 3a. Fixed effect model for Change from Baseline in MADRS and Odds Ratio for Response. Table 3b. Fixed effect model for Change from Baseline in CGI-BP-S-depression and CGI-BP-S-overall. Table 3c. Fixed effect model for Odds Ratios for Remission (MADRS ≤ 12) and Remission (MADRS ≤ 10). Table 4a. Fixed effect model for Odds Ratios for All-Cause Discontinuation and Discontinuation Due to Adverse Events. Table 4b. Fixed effect model for Odds Ratios for Discontinuation Due Lack of Efficacy. Table 5a. Fixed effect model for Change from Baseline in Weight and Odds Ratios of ≥ 7% Weight Gain. Table 5b. Fixed effect model for Change from Baseline in Triglycerides and Total Cholesterol. Table 5c. Fixed effect model for Change from Baseline in Low-Density Lipoprotein Cholesterol and Glucose. Table 5d. Fixed effect model for Change from Baseline in Prolactin. Table 6a. Fixed effect model for Odds Ratios for Somnolence and Switch to Mania. Table 6b. Fixed effect model for Odds Ratios for Extrapyramidal Symptoms and Akathisia. Table 7a. GRADE assessment of Continuous Outcomes. Table 7b. GRADE assessment of Dichotomous Outcomes. Table 8. Heterogeneity Assessment through Tau2 of the networks. Figure 1a. Network Diagrams for Change from Baseline in MADRS, CGI-BP-S Overall, CGI-BP-S-Depression, Weight and Blood Glucose. Figure 1b. Network Diagrams for Change from Baseline in Triglycerides, Total Cholesterol, Low-Density Lipoprotein Cholesterol and Prolactin. Figure 1c. Network Diagrams for Response, Remission (MADRS ≤ 12 and ≤ 10), All Cause Discontinuation, Discontinuation due to Lack of Efficacy and Discontinuation due to Adverse Events. Figure 1d. Network Diagrams for ≥ 7% weight gain, Akathisia, Switch to Mania, Extrapyramidal Symptoms and Somnolence. Figure 2. Risk of Bias Assessment of Included Studies. Figure 3a. Assessment of Publication Bias Through Funnel Plots for Change from Baseline in MADRS, CGI-BP-S Overall, CGI-BP-S-Depression, Weight and Blood Glucose. Figure 3b. Assessment of Publication Bias Through Funnel Plots for Triglycerides, Total Cholesterol, Low-Density Lipoprotein Cholesterol and Prolactin. Figure 3c. Assessment of Publication Bias Through Funnel Plots for Response, Remission (MADRS ≤ 12 and ≤ 10), All Cause Discontinuation, Discontinuation due to Lack of Efficacy and Discontinuation due to Adverse Events. Figure 3d. Assessment of Publication Bias Through Funnel Plots for ≥ 7% weight gain, Akathisia, Switch to Mania, Extrapyramidal Symptoms and Somnolence. Figure 4a. Heterogeneity Assessment of Included RCTs Through Effect Modifier Comparison. Figure 4b. Heterogeneity Assessment of Included RCTs Through Effect Modifier Comparison (Contd.).